Opus Genetics, Inc. (IRD) stock
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30460% above fair value
$3.98−0.08 (-1.97%)
Close on Nov 13, 2026Market cap $331.12MP/E –Yield –
Opus Genetics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Opus Genetics's price to sales ratio was 36.1× on Nov 11, 2026, against 9.4× a year earlier. Over the last 5 years it ranged from 1.0× to 109.4×, with a median of 4.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 36.1× | +27.3 |
| 2025 | Dec 31, 2025 | 8.9× | +5.1 |
| 2024 | Dec 31, 2024 | 3.7× | +2.5 |
| 2023 | Dec 29, 2023 | 1.2× | −95.4 |
| 2022 | Oct 31, 2022 | 96.6× | +51.1 |
| 2021 | Jan 29, 2021 | 45.5× | +20.2 |
| 2020 | Dec 31, 2020 | 25.3× | – |
See a number that looks wrong?